{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:34:28Z","timestamp":1763966068717,"version":"3.45.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Anthracycline-induced cardiotoxicity is a major concern in cancer treatment, as it can lead to various arrhythmias, with frequent premature ventricular contractions (PVCs) being one of the most common types.\n                      <jats:italic>Sheng Mai Yin<\/jats:italic>\n                      (SMY), a widely used Chinese herbal compound in China, has shown potential in treating anthracycline-induced cardiac dysfunction and arrhythmias. However, the evidence supporting its efficacy is limited due to methodological flaws in prior studies. Therefore, high-quality trials are essential to rigorously evaluate the efficacy and safety of SMY.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter, randomized, double-blind, placebo-controlled trial will assess the efficacy and safety of SMY in treating frequent PVCs induced by anthracycline chemotherapy. A total of 212 patients with breast cancer or malignant lymphoma undergoing anthracycline-based chemotherapy, who have been diagnosed with new-onset frequent PVCs and\n                      <jats:italic>Qi<\/jats:italic>\n                      and\n                      <jats:italic>Yin<\/jats:italic>\n                      deficiency syndrome, will be enrolled. Participants will be randomly assigned to receive either SMY or a placebo for 8 weeks, alongside standard medications. The primary outcome is the reduction rate in PVC frequency. Secondary outcomes include PVC symptom scores, Traditional Chinese Medicine syndrome scores, cardiac dysfunction biomarkers, and major adverse cardiovascular events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The results of this trial are expected to provide robust evidence regarding the efficacy and safety of SMY in the treatment of anthracycline-induced frequent PVCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>http:\/\/itmctr.ccebtcm.org.cn<\/jats:ext-link>\n                      . Registration number: ITMCTR2024000858.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1670053","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:29:28Z","timestamp":1763965768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigation of Sheng Mai Yin in the treatment of anthracycline-induced frequent premature ventricular contractions in cancer patients: study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Qiwen","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaofeng","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tangshun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ce","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longzhen","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duolao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5114\/aoms.2016.59270","article-title":"Cardiotoxicity of anthracycline therapy: current perspectives","volume":"12","author":"Valcovici","year":"2016","journal-title":"Arch Med Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.amjmed.2021.05.026","article-title":"Chemotherapy-induced arrhythmia\u2014underrecognized and undertreated","volume":"134","author":"Essa","year":"2021","journal-title":"Am J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","article-title":"Anthracycline-induced cardiotoxicity\u2014are we about to clear this hurdle?","volume":"185","author":"Dempke","year":"2023","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/0002-8703(81)90611-6","article-title":"Arrhythmias documented by 24-hour continuous ambulatory electrocardiographic monitoring in young women without apparent heart disease","volume":"101","author":"Sobotka","year":"1981","journal-title":"Am Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1067\/mhj.2002.120298","article-title":"Prevalence of premature ventricular contractions in a population of African American and white men and women: the atherosclerosis risk in communities (ARIC) study","volume":"143","author":"Simpson","year":"2002","journal-title":"Am Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.119.042434","article-title":"Evaluation and management of premature ventricular complexes","volume":"141","author":"Marcus","year":"2020","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3109\/02841869109091832","article-title":"Cardiac arrhythmias in patients with small cell lung cancer and cardiac disease before, during and after doxorubicin administration an evaluation of acute carditoxicity by continuous 24-hour holter monitoring","volume":"30","author":"Raabe","year":"1991","journal-title":"Acta Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0002-9149(92)91393-I","article-title":"Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults","volume":"70","author":"Larsen","year":"1992","journal-title":"Am J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/01.smj.0000257382.89910.fe","article-title":"Early and late arrhythmogenic effects of doxorubicin","volume":"100","author":"Kilickap","year":"2007","journal-title":"South Med J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40880-018-0343-7","article-title":"The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study","volume":"38","author":"Liu","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5582\/bst.2021.01318","article-title":"The positive role of traditional Chinese medicine as an adjunctive therapy for cancer","volume":"15","author":"Zhang","year":"2021","journal-title":"Biosci Trends"},{"key":"B16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jtcms.2014.09.005","article-title":"Biologic basis of TCM syndromes and the standardization of syndrome classification","volume":"1","author":"Cheng","year":"2014","journal-title":"J Tradit Chin Med Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"154433","DOI":"10.1016\/j.phymed.2022.154433","article-title":"Shengmai san-derived compound prescriptions: a review on chemical constituents, pharmacokinetic studies, quality control, and pharmacological properties","volume":"107","author":"Ouyang","year":"2022","journal-title":"Phytomedicine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s11655-022-2884-5","article-title":"Shengmai san for treatment of cardiotoxicity from anthracyclines: a systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Chin J Integr Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"103053","DOI":"10.1016\/j.ctim.2024.103053","article-title":"Effect of shenmai injection on anthracycline-induced cardiotoxicity: a systematic review and meta-analysis","volume":"83","author":"Yang","year":"2024","journal-title":"Complement Ther Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e081477","DOI":"10.1136\/bmj-2024-081477","article-title":"SPIRIT 2025 Statement: updated guideline for protocols of randomised trials","volume":"389","author":"Chan","year":"2025","journal-title":"Br Med J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.19401\/j.cnki.1007-3639.2023.12.004","article-title":"Guidelines for breast cancer diagnosis and treatment by China anti-cancer association (2024 edition)","volume":"33","year":"2023","journal-title":"China Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2021.03.01","article-title":"Union for China lymphoma investigators of Chinese society of clinical oncology. Chinese society of clinical oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)","volume":"33","author":"Zhu","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3760\/cma.j.cn.113859-20200509-00116","article-title":"2020 Chinese society of pacing and electrophysiology (CSPE)\/Chinese society of arrhythmias (CSA) expert consensus statement on ventricular arrhythmias (2016 update)","volume":"24","year":"2020","journal-title":"Chin J Card Arrhythmias"},{"key":"B24","article-title":"Guiding principles for clinical study of new chinese medicines","year":""},{"key":"B25","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.4103\/0366-6999.166026","article-title":"The efficacy and safety of Wenxin Keli in patients with frequent premature ventricular contractions: a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial","volume":"128","author":"Hua","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"B26","article-title":"Chinese society of clinical oncology (CSCO) cardio-oncology guidelines 2023","year":"2023"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/ehjci\/jex033","article-title":"2d and 3d strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility","volume":"18","author":"Santoro","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"Br Med J"},{"key":"B30","first-page":"835","volume-title":"Pharmacopoeia of the People\u2019s Republic of China (Part 1, 2020 Edition)","year":"2020"},{"key":"B31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","article-title":"Cancer chemotherapy and cardiac arrhythmias: a review","volume":"38","author":"Tamargo","year":"2015","journal-title":"Drug Saf"},{"key":"B32","doi-asserted-by":"publisher","first-page":"104542","DOI":"10.1016\/j.phrs.2019.104542","article-title":"Doxorubicin and its proarrhythmic effects: a comprehensive review of the evidence from experimental and clinical studies","volume":"151","author":"Benjanuwattra","year":"2020","journal-title":"Pharmacol Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jgr.2019.06.005","article-title":"Antiarrhythmic effects of ginsenoside Rg2 on calcium chloride\u2013induced arrhythmias without oral toxicity","volume":"44","author":"Gou","year":"2020","journal-title":"J Ginseng Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"105843","DOI":"10.1016\/j.phrs.2021.105843","article-title":"Rg3 promotes the SUMOylation of SERCA2a and corrects cardiac dysfunction in heart failure","volume":"172","author":"Liu","year":"2021","journal-title":"Pharmacol Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1124\/jpet.114.219261","article-title":"Ophiopogonin d attenuates doxorubicin-induced autophagic cell death by relieving mitochondrial damage in vitro and in vivo","volume":"352","author":"Zhang","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0119214","DOI":"10.1371\/journal.pone.0119214","article-title":"Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK\/p53 signaling","volume":"10","author":"Thandavarayan","year":"2015","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1152\/physrev.00018.2010","article-title":"CaMKII in the cardiovascular system: sensing redox states","volume":"91","author":"Erickson","year":"2011","journal-title":"Physiol Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1142\/S0192415X06003849","article-title":"Sheng-Mai-San reduces adriamycin-induced cardiomyopathy in rats","volume":"34","author":"You","year":"2006","journal-title":"Am J Chin Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12906-016-1037-9","article-title":"Protective effect of Sheng-Mai Yin, a traditional Chinese preparation, against doxorubicin-induced cardiac toxicity in rats","volume":"16","author":"Ma","year":"2016","journal-title":"BMC Complement Altern Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by the association for European Paediatric and Congenital Cardiology (AEPC)","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.jacc.2017.10.053","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1670053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:29:30Z","timestamp":1763965770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1670053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":43,"alternative-id":["10.3389\/fcvm.2025.1670053"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1670053","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"article-number":"1670053"}}